Medicine and Public Issues3 October 2017
    Author, Article, and Disclosure Information


    The U.S. Department of Veterans Affairs (VA) is the nation's largest care provider for hepatitis C virus (HCV)–infected patients and is uniquely suited to inform national efforts to eliminate HCV. An extensive array of delivery of services, policy guidance, outreach efforts, and funding has broadened the reach and capacity of the VA to deliver direct-acting antiviral (DAA) HCV therapy, supported by an infrastructure to effectively implement change and informed by extensive population health data analysis. The VA has treated more than 92 000 HCV-infected veterans since all-oral DAAs became available in January 2014, with cure rates exceeding 90%; only 51 000 veterans in VA care are known to remain potentially eligible for treatment. Key actions advancing the VA's aggressive treatment of HCV infection that are germane to non-VA settings include expansion of treatment capacity through the use of nonphysician providers, video telehealth, and electronic technologies; expansion of integrated care to address psychiatric and substance use comorbidities; and electronic data tools for patient tracking and outreach. A critical component of effective implementation has been building infrastructure through the creation of regional multidisciplinary HCV Innovation Teams, whose system redesign efforts have produced innovative HCV practice models addressing gaps in care while providing more efficient and effective HCV management for the populations they serve. Financing for HCV treatment and infrastructure resources coupled with reduced drug prices has been paramount to the VA's success in curing HCV infection. The VA is poised to share and extend best practices to other health care organizations and providers delivering HCV care, contributing to a concerted effort to reduce the overall burden of HCV infection.


    • 1. National Academies of Sciences, Engineering,and MedicineA National Strategy for the Elimination of Hepatitis B and C: Phase Two Report Phase Two ReportPhase Two Report. Washington, DC: National Academies Pr; 2017. [PMID: 28737845] doi:10.17226/24731 CrossrefMedlineGoogle Scholar
    • 2. Buckley GJStrom BLA national strategy for the elimination of viral hepatitis emphasizes prevention, screening, and universal treatment of hepatitis C. Ann Intern Med2017;166:895-6. [PMID: 28384754]. doi:10.7326/M17-0766 LinkGoogle Scholar
    • 3. Beste LAIoannou GNPrevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs. Epidemiol Rev2015;37:131-43. [PMID: 25600415] doi:10.1093/epirev/mxu002 CrossrefMedlineGoogle Scholar
    • 4. Surface Transportation and Veterans Health Care Choice Improvement Act of 2015, H.R. 3236, 114th Cong. (2015–2016). Google Scholar
    • 5. U.S. Department of Veterans Affairs. Viral Hepatitis. Updated 20 July 2017. Accessed at on 20 April 2017. Google Scholar
    • 6. Backus LIBelperio PSShahoumian TALoomis TPMole LAReal-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients. Antivir Ther2016. [PMID: 27934775] doi:10.3851/IMP3117 CrossrefMedlineGoogle Scholar
    • 7. Ioannou GNBeste LAChang MFGreen PKLowy ETsui JIet alEffectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs national health care system. Gastroenterology2016;151:457-71. [PMID: 27267053] doi:10.1053/j.gastro.2016.05.049 CrossrefMedlineGoogle Scholar
    • 8. Maier MMRoss DBChartier MBelperio PSBackus LICascade of care for hepatitis C virus infection within the US Veterans Health Administration. Am J Public Health2016;106:353-8. [PMID: 26562129] doi:10.2105/AJPH.2015.302927 CrossrefMedlineGoogle Scholar
    • 9. Backus LIGavrilov SLoomis TPHalloran JPPhillips BRBelperio PSet alClinical case registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc2009;16:775-83. [PMID: 19717794] doi:10.1197/jamia.M3203 CrossrefMedlineGoogle Scholar
    • 10. Smith BDMorgan RLBeckett GAFalck-Ytter YHoltzman DTeo CGet alCenters for Disease Control and PreventionRecommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep2012;61:1-32. [PMID: 22895429] MedlineGoogle Scholar
    • 11. Moyer VAU.S. Preventive Services Task ForceScreening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med2013;159:349-57. [PMID: 23798026]. doi:10.7326/0003-4819-159-5-201309030-00672 LinkGoogle Scholar
    • 12. Backus LIBelperio PSLoomis TPMole LAImpact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care. Am J Public Health2014;104 Suppl 4:S555-61. [PMID: 25100421] doi:10.2105/AJPH.2014.302090 CrossrefMedlineGoogle Scholar
    • 13. Noska AJBelperio PSLoomis TPO'Toole TPBackus LIEngagement in the hepatitis C care cascade among homeless veterans, 2015. Public Health Rep2017;132:136-9. [PMID: 28135425] doi:10.1177/0033354916689610 CrossrefMedlineGoogle Scholar
    • 14. Jonas MCRodriguez CVRedd JSloane DAWinston BJLoftus BCStreamlining screening to treatment: the hepatitis C cascade of care at Kaiser Permanente Mid-Atlantic states. Clin Infect Dis2016;62:1290-6. [PMID: 26908812] doi:10.1093/cid/ciw086 CrossrefMedlineGoogle Scholar
    • 15. Ross DB, Gonzalez R, Morgan T, Park A. Best practices in screening, diagnosis, and treatment along the Veteran Health Administration's cascade of HCV care. In: Addressing the Unique Needs of Military Veterans With Chronic HCV Infection. Federal Practitioner Supplement. 1 February 2017. Google Scholar
    • 16. Toussaint JSBerry LLThe promise of Lean in health care. Mayo Clin Proc2013;88:74-82. [PMID: 23274021] doi:10.1016/j.mayocp.2012.07.025 CrossrefMedlineGoogle Scholar
    • 17. Rogal SSYakovchenko VWaltz TJPowell BJKirchner JEProctor EKet alThe association between implementation strategy use and the uptake of hepatitis C treatment in a national sample. Implement Sci2017;12:60. [PMID: 28494811] doi:10.1186/s13012-017-0588-6 CrossrefMedlineGoogle Scholar
    • 18. Arora SKalishman SThornton KDion DMurata GDeming Pet alExpanding access to hepatitis C virus treatment—Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology2010;52:1124-33. [PMID: 20607688] doi:10.1002/hep.23802 CrossrefMedlineGoogle Scholar
    • 19. Beste LAGlorioso TJHo PMAu DHKirsh SRTodd-Stenberg Jet alTelemedicine specialty support promotes hepatitis C treatment by primary care providers in the Department of Veterans Affairs. Am J Med2017;130:432-8. [PMID: 27998682] doi:10.1016/j.amjmed.2016.11.019 CrossrefMedlineGoogle Scholar
    • 20. Rongey CShen HHamilton NBackus LIAsch SMKnight SImpact of rural residence and health system structure on quality of liver care. PLoS One2013;8:e84826. [PMID: 24386420] doi:10.1371/journal.pone.0084826 CrossrefMedlineGoogle Scholar
    • 21. Backus LIBelperio PSShahoumian TAMole LAImpact of provider type on hepatitis C outcomes with boceprevir-based and telaprevir-based regimens. J Clin Gastroenterol2015;49:329-35. [PMID: 24667591] doi:10.1097/MCG.0000000000000124 CrossrefMedlineGoogle Scholar
    • 22. Ourth HGroppi JMorreale APQuicci-Roberts KClinical pharmacist prescribing activities in the Veterans Health Administration. Am J Health Syst Pharm2016;73:1406-15. [PMID: 27605319] doi:10.2146/ajhp150778 CrossrefMedlineGoogle Scholar
    • 23. Tsui JIWilliams ECGreen PKBerry KSu FIoannou GNAlcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend2016;169:101-9. [PMID: 27810652] doi:10.1016/j.drugalcdep.2016.10.021 CrossrefMedlineGoogle Scholar
    • 24. U.S. Department of Veterans Affairs. VA expands hepatitis C drug treatment [press release]. Washington, DC: U.S. Department of Veterans Affairs; 9 March 2016. Accessed at on 10 April 2017. Google Scholar
    • 25. Bhattacharya DBelperio PSShahoumian TALoomis TPGoetz MBMole LAet alEffectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Clin Infect Dis2017;64:1711-20. [PMID: 28199525] doi:10.1093/cid/cix111 CrossrefMedlineGoogle Scholar
    • 26. El-Serag HBKramer JDuan ZKanwal FEpidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat2016;23:687-96. [PMID: 27040447] doi:10.1111/jvh.12533 CrossrefMedlineGoogle Scholar
    • 27. Yehia BRSchranz AJUmscheid CALo Re VThe treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One2014;9:e101554. [PMID: 24988388] doi:10.1371/journal.pone.0101554 CrossrefMedlineGoogle Scholar
    • 28. Spradling PRRupp LMoorman ACLu MTeshale EHGordon SCet alChronic Hepatitis Cohort Study InvestigatorsHepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis2012;55:1047-55. [PMID: 22875876] CrossrefMedlineGoogle Scholar
    • 29. Holmberg SDSpradling PRMoorman ACDenniston MMHepatitis C in the United States. N Engl J Med2013;368:1859-61. [PMID: 23675657] doi:10.1056/NEJMp1302973 CrossrefMedlineGoogle Scholar